Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of efficacy and safety of insulin detemir in combination with insulin aspart and biphasic insulin aspart 30 [insulin aspart/insulin protamine aspart] in type 2 diabetes mellitus.

Next Previous
Trial Profile

Comparison of efficacy and safety of insulin detemir in combination with insulin aspart and biphasic insulin aspart 30 [insulin aspart/insulin protamine aspart] in type 2 diabetes mellitus.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin detemir (Primary) ; Insulin aspart/insulin protamine aspart
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms PreFER
  • Sponsors Novo Nordisk

Most Recent Events

  • 01 Jul 2009 Actual end date (1 Mar 2005) added as reported by ClinicalTrials.gov.
  • 01 Jan 2009 Results have been published in Diabetes, Obesity and Metabolism.
  • 01 Jan 2009 Primary endpoint 'Proportion of glycosylated haemoglobin' has been met according to results published in Diabetes, Obesity and Metabolism.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top